Development of Cytarabine Prodrugs and Delivery Systems for Leukemia Treatment

Expert Opinion on Drug Delivery - United Kingdom
doi 10.1517/17425247.2010.527330
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa Healthcare

Related search

Cytarabine Dose for Acute Myeloid Leukemia

New England Journal of Medicine
Medicine
2011English

Dose Intensification of Daunorubicin and Cytarabine During Treatment of Adult Acute Lymphoblastic Leukemia

Cancer
Cancer ResearchOncology
2012English

Synthesis and Evaluation of Esmolol Prodrugs for Transdermal Delivery

Drug Delivery
MedicinePharmaceutical Science
2010English

Low Dose Cytarabine and Cladribine for Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Clinical Experience

Klinicheskaya Onkogematologiya/Clinical Oncohematology
OncologyHematology
2016English

Organic Nanoparticles as Drug Delivery Systems and Their Potential Role in the Treatment of Chronic Myeloid Leukemia

Technology in Cancer Research and Treatment
MedicineCancer ResearchOncology
2019English

Pulmonary Drug Delivery Systems for the Treatment of Tuberculosis

Drug Delivery System
Pharmaceutical Science
2008English

Redox Activation of Metal-Based Prodrugs as a Strategy for Drug Delivery

Advanced Drug Delivery Reviews
Pharmaceutical Science
2012English

A Phase I Trial of Ribavirin and Low-Dose Cytarabine for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia With Elevated eIF4E

Haematologica
Hematology
2014English

Development of Prodrugs for PDT-Based Combination Therapy Using a Singlet-Oxygen-Sensitive Linker and Quantitative Systems Pharmacology

Journal of Clinical Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy